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ABSTRACT
Background: A low level of evidence exists
regarding the choice of calcineurin inhibitor
(CNI) for immunosuppression after lung trans-
plantation (LTx). Therefore, we designed a ran-
domized clinical trial according to good clinical
practice rules to compare tacrolimus with
cyclosporine after LTx.
Methods: The ScanCLAD study is an investiga-
tor-initiated, pragmatic, controlled, randomized,
open-label, multicenter study evaluating if an
immunosuppressive protocol based on anti-
thymocyte globulin (ATG) induction, once-daily
tacrolimus dose, mycophenolate mofetil, and
corticosteroid reduces the incidence of chronic
lung allograft dysfunction (CLAD) after LTx,
compared to a cyclosporine-based protocol with
all other immunosuppressive and prophylactic
drugs being identical between groups. All patients
will be followed for 3 years to determine the main
endpoint of CLAD. The study is designed for
superiority, and power calculations show that 242
patients are needed. Also, the study is designed
with more than 10 substudies addressing other
important and unresolved issues in LTx. In addi-
tion, the ScanCLAD study enabled the synchro-
nization of the treatment and follow-up protocols
of the lung transplantation programs of all five
Scandinavian lung transplantation centers.
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Planned Outcomes: Recruitment started in
2016. At the end of April 2019, 227 patients were
randomized. We anticipate the last patient to be
randomized in autumn 2019, and thus the last
patient visits will be in 2022. The ScanCLAD study
is enrolling and investigates which CNI is to be
preferred from a CLAD perspective after LTx.
Trial Registry Number: ScanCLAD trial regis-
tered at ClinicalTrials.gov before patient
enrollment (NCT02936505). EUDRACT number
2015-004137-27.
Keywords: Lung transplantation; Calcineurin
inhibitor; Chronic lung allograft dysfunction;
Randomized clinical trial
Key Summary Points
Why carry out this study?
A calcineurin inhibitor (CNI) is considered
essential after lung transplantation (LTx)
but few randomized controlled trials
(RCT) exploring the differences between
cyclosporine and tacrolimus exist in LTx.
Therefore, we wanted to test whether
chronic lung allograft dysfunction (CLAD)
would be more prevalent with
cyclosporine or tacrolimus in a RCT.
The ScanCLAD study is an investigator
initiated, pragmatic, controlled,
randomized, open-label, multi-center study
evaluating if an immunosuppressive
protocol based on ATG-induction, once
daily tacrolimus-dose, mycophenolate
mofetil and corticosteroid reduces the
incidence of CLAD after LTx, compared to a
cyclosporine-based protocol with all other
immunosuppressive and prophylactic
drugs being identical between groups.
What was learned from the study?
The ScanCLAD study is enrolling and
investigates which CNI is to be preferred
from a CLAD perspective after LTx.
The ScanCLAD study is designed with
more than 10 sub-studies addressing other
important and unresolved issues in LTx..
INTRODUCTION
A calcineurin inhibitor (CNI) is considered
essential after lung transplantation (LTx). Both
cyclosporine and tacrolimus are used as CNI
after LTx. In Scandinavia we have used cyclos-
porine for a long time, and still do, with good
results in LTx [1, 2]. Few randomized controlled
trials (RCT) exploring the differences between
cyclosporine and tacrolimus exist in LTx [3],
and despite this most centers around the world
have switched to tacrolimus [4].
Chronic rejection after LTx is characterized
by a decline in lung function and was previ-
ously considered equivalent to bronchiolitis
obliterans syndrome (BOS). Nowadays chronic
rejection is referred to as chronic lung allograft
dysfunction (CLAD) [5]. CLAD includes the
older description BOS characterized by small
airway fibrosis and obstructive lung physiology
and a restrictive allograft syndrome (RAS)
characterized by parenchymal/pleural fibrosis
and a restrictive physiology. The definition of
both CLAD and RAS has recently been updated
[6, 7].
Therefore, in a regular clinical setting where
most adult patients undergoing LTx would be
eligible for inclusion, we wanted to test whether
CLAD would be more prevalent with cyclos-
porine or tacrolimus.
METHODS
Study Aim
The aim of the study is to evaluate whether
immunosuppression based on a once-daily
tacrolimus dose regimen (Advagraf), with anti-
thymocyte globulin (Thymoglobulin) induc-
tion, mycophenolate mofetil (MMF), and corti-
costeroids (CS), reduces the cumulative
incidence of CLAD after de novo LTx at
36 months, in comparison with a twice-daily
cyclosporine-based protocol, with otherwise
identical treatment between groups.
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Study Design
This is an investigator-initiated, prospective,
Scandinavian (multinational), multicenter,
randomized, controlled, parallel group, and
open-label study in de novo lung transplant
recipients. Patients fulfilling all of the inclusion
and none of the exclusion criteria will be ran-
domized to one of the two treatment groups.
Enrollment will be continued until the required
sample size is achieved. This multicenter study
was first approved by the Ethics Review Board
(D.nr 154-16) at the University of Gothenburg
as well as by the Medical Product Agency in
Sweden (EUDRACT number 2015-004137-27,
D.nr 5.1 2016-31518), and subsequently by the
corresponding authorities in Denmark, Finland,
and Norway. Therefore, ethics committees (EC)
of all the Scandinavian countries have approved
the final study protocol, including the final
version of the informed consent form, and the
following amendments of the protocol, includ-
ing all substudies. In addition, medical product
agencies in all four participating countries have
approved the study. Written informed consent
will be obtained before any study-related pro-
cedures are implemented. The study will be
performed in accordance with ethical principles
that have their origin in the Declaration of
Helsinki and are consistent with ICH–GCP and
applicable local regulatory requirements. The
study was registered at ClinicalTrial.gov
(NCT02936505) well before the first patient was
included in the study.
Study Objectives and Endpoints
The primary objective is to compare the efficacy
between treatment regimes by assessing the
difference in CLAD incidence at 36 months
after LTx.
Secondary endpoints are outlined in Table 1.
Many of these are the basis for separate
substudies.
Study Population
The study population will consist of a repre-
sentative group (n = 242) of de novo lung
transplant patients who fulfill the requirements
according to inclusion and exclusion criteria
(Table 2). The intention is that it will be possible
for most patients eligible for LTx in Scandinavia
to be included in the study, with the exception
of those undergoing re-transplantation, single
lung transplantation, and recipients under the
age of 18. The patients are randomized imme-
diately prior to transplantation to receive a
standard immunosuppressive protocol of
cyclosporine, MMF and CS—group A, or a
combination of tacrolimus, MMF, and CS—
group B (Fig. 1). The patients will be recruited
from all five Scandinavian centers for lung
transplantation: Copenhagen, Denmark;
Gothenburg, Sweden; Helsinki, Finland; Lund,
Sweden; and Oslo, Norway. Since the study is
designed as an ‘‘all in study’’ (however, pedi-
atrics and re-transplantations are excluded), the
expected inclusion time was calculated to be
2 years since the annual volume is approxi-
mately 140 LTx (mean of 142 LTx during
2012–2016, and stratified by center: Gothen-
burg 43; Lund 16; Oslo 32; Helsinki 20; and
Copenhagen 31) among Scandinavian
institutions.
Substudies
The ScanCLAD study includes a number of
separate substudies addressing important and
unanswered questions, which are of interest
regardless of the outcome of the main study. All
substudies are shown in Table 3. Each substudy
has its own responsible principle investigator
(PI), and most include patients from all sites.
The substudies have separate protocols and
budgets.
Clinical Assessment
All assessments and visits are shown in Table 4.
All the obtained data must be supported in the
patient’s medical records, i.e., source docu-
mentation, and subsequently stored in an elec-
tronic case record form (eCRF). Management of
immunosuppressive regime of the ScanCLAD
study is outlined in Table 5. Azithromycin will
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Table 1 Secondary objectives
To compare the efﬁcacy between treatment regimes by assessing the difference in
Renal function evaluated by mGFR at 3 months after LTx
The composite measure of freedom from allograft rejection, CLAD, graft survival, and patient survival at 12, 24, and
36 months after transplantation
The cumulative incidence of PGD at 72 h
Patient survival at 1 and 3 years
The cumulative incidence of acute allograft rejection and CLAD at 6 months, 1 year, and 3 years
The cumulative incidence of BOS and RAS at 6 months, 1 year, and 3 years
Development of DSA at 12, 24, and 36 months
Renal function evaluated by mGFR, by iohexol or Cr-EDTA clearance, at 12, 24, and 36 months
Renal function evaluated by cGFR, by three different formulas, at 3, 12, 24, and 36 months
The cumulative incidence of PTDM at 6, 12, 24, and 36 months after transplantation
Use of antidiabetic medication at 6, 12, 24, and 36 months
Incidence and number of antihypertensive and lipid-lowering drugs at 12, 24, and 36 months
Development and magnitude of proteinuria at 12, 24, and 36 months
Lipid proﬁle at 12, 24, and 36 months
Incidence of CMV that required treatment (CMV infection or CMV syndrome)
Cumulative incidence of malignancy stratiﬁed by PTLD and all other cancers, at 36 months
Safety and tolerability
Quality of life, assessed by EQ 5D3L and SGRQ, both self-administered, pre-transplant and at 12, 24, and 36 months
Deﬁne the pharmacokinetics of tacrolimus in patients without CF (n = 12) and all included patients with CF
(n = 15–20) undergoing primary lung transplantation treated with Advagraf-based immunosuppression
Immunological equipotency of tacrolimus and cyclosporine in vivo and in vitro
Occurrence of treatment failures up to or at 36 months; deﬁned as a composite endpoint of graft loss, death, loss to
follow-up or discontinuation due to lack of efﬁcacy or toxicity (at least one condition must be present)
Recovery of right heart function irrespective of diagnosis in patients with PAH (categories 1–5 according to WHO
1–5)
BOS bronchiolitis obliterans syndrome, CF cystic ﬁbrosis, cGFR calculated glomerular ﬁltration rate, CLAD chronic lung
allograft dysfunction, CMV cytomegalovirus, DSA donor-speciﬁc antibodies, ISHLT International Society of Heart and
Lung Transplantation, LTx lung transplantation, mGFR measured glomerular ﬁltration rate, PAH pulmonary arterial
hypertension, RAS restrictive allograft syndrome, PGD primary graft dysfunction, PTDM post-transplantation diabetes
mellitus, PTLD post-transplant lymphoproliferative disorder, SGRQ St Georges Respiratory Questionnaire, WHO World
Health Organization
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not be performed as prophylaxis treatment,
only when CLAD is suspected or diagnosed.
Efficacy Measurements
The following efficacy variables will be obtained
and recorded:
• Lung function testing: Experienced and skilled
technicians in a specialized respiratory labo-
ratory will perform the pulmonary function
tests. The quality control and performance
of spirometry, measurements of lung vol-
umes, and carbon monoxide uptake (CO
uptake), i.e., transfer factor or diffusing
capacity (DLCO), are in accordance with
the European recommendations [8–10].
Spirometry is performed on a rolling seal
spirometer. The forced expiratory vital
capacity (FVC) and forced expiratory volume
in first second (FEV1) are taken as the
highest of repeated recordings. Lung vol-
umes, i.e., total lung capacity (TLC), func-
tional residual capacity (FRC), and residual
volume (RV), are obtained in a body plethys-
mograph. CO uptake is obtained by the
single-breath method using standard equip-
ment. Volume and gas concentration
Table 2 Inclusion and exclusion criteria
Inclusion criteria
Male or female lung recipients 18–70 years of age undergoing primary double (including size reduction) lung
transplantation
Patient willing and capable of giving written informed consent for study participation and anticipated to be able to
participate in the study for 36 months
Exclusion criteria
Recipients of multiorgan transplant, and/or previously transplanted with any organ, including previous lung
transplantation
Patients with hypersensitivity to or other reasons to not be able to take the immunosuppressive drugs used in the study
Donor lung cold ischemic time[ 12 h
Patients who previously have been treated with anti-thymocyte globulin preparations (e.g., ATG-Fresenius,
Thymoglobulin)
Patients who are recipients of ABO-incompatible transplants
Patients with platelet count\ 50,000/mm3 at the evaluation before transplantation
Patients who are unlikely to comply with the study requirements
Patients, and/or those receiving organs from donors, who are positive for HIV, hepatitis B surface antigen, or
hepatitis C virus
Patients with donor older than 75 years
Patient who have received an unlicensed drug or therapy within 1 month prior to study entry or if such therapy is to be
instituted post-transplantation
Patient unable to participate in the study for the full 36-month period
Patients with any past (within the past 3 years (low-risk malignancy) to 5 years (high-risk malignancy)) or present
malignancy (other than excised basal cell carcinoma)
Women capable of becoming pregnant must have a negative pregnancy test prior to randomization
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Fig. 1 Design of the ScanCLAD study. LTx lung transplantation, CNI calcineurin inhibitor, CyA cyclosporine, BID twice
daily, MMF mycophenolate mofetil, CS corticosteroids, Tac tacrolimus, OD once daily
Table 3 Substudies of the main ScanCLAD study
Donor-speciﬁc antibodies in chronic lung allograft dysfunction
PTDM in lung transplantation
Equipotency of tacrolimus and cyclosporine in vivo and in vitro
Quality of life after lung transplantation in Scandinavia
Cytomegalovirus as a risk factor for CLAD and its subtypes BOS and RAS
Imaging in primary graft dysfunction
Clinical pharmacokinetics of once-daily prolonged release tacrolimus in cystic ﬁbrosis compared to non-cystic ﬁbrosis
lung transplant recipients
Recovery of RV failure in PAH after lung transplantation
Lung donor characteristics as risk factors for PGD and CLAD
Molecular biomarkers as potential targets for therapeutic strategies after lung transplantation
Correlation of the incidence of acute rejection with the non-invasive blood transcriptional assay (SORT)
Weight-to-height ratio as a predictor for CLAD and overall survival after lung transplantation
Cytokines and inﬂammatory variables in lung-transplanted recipients
AMR in lung transplantation: treatment and risk factors
CLAD subtypes, BOS and RAS, deﬁned by computed tomography volumetry
AMR antibody-mediated rejection, CLAD chronic lung allograft dysfunction, BOS bronchiolitis obliterans syndrome, PGD
primary graft dysfunction, PTDM post-transplantation diabetes mellitus, RAS restrictive allograft syndrome
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Table 4 Assessment schedule
Period Period 1 Period 2
Visit 1 2 3 4 5 6 7 8 9 10
Week/month Pre-
LTx
LTx W1 W4 M3 M6 M9 M12 M24 M36
Informed consent x
Inclusion/exclusion x x
Randomization x
Demography x
General medical history x
Transplantation information x
Background donor x
Protocol biopsy x x x
HLA typing x
HLAab/DSA (stored) x x x x x x x
Vital signs x x x x x x x x x x
Lung function test Spiro, DLCO, VOL x x x x x x x x
6 min walk test x x x x
Quality of life x x x x
Laboratory test
Hematology/biochemistry x x x x x x x x x x
Lipid proﬁle x x x x x
Viral serology and PCR x x x x x x x x
Flow cytometry (T cell activation) & ImmunKnow
assay
x x x x x
Pregnancy test x
Urinalysis x x x x x x x
cGFR x x x x x x x
mGFR x x x x x
HR-CT scan x x x x x x
Drug concentration
Cya/Tac blood conc level x x x x x x x x
MPA blood conc level x x
Echocardiography in PAH x x x x x x
DNA/RNA isolation X x x x x x
Tac pharmacokinetics x x
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calibrations are checked daily. At visits 4 and
7 only spirometry will be performed without
volumes or DLCO. The baseline value is
defined as the mean of the two best FEV1
values post LTx, from which CLAD will be
determined (and FVC will be used to dis-
criminate between BOS and RAS) according
to the most updated recommendations [7].
• Measured glomerular filtration rate (mGFR):
The mGFR is the best clinical estimate of
renal function in health and disease, and
correlates well with the clinical severity of
renal function disturbances also after trans-
plantation [11]. GFR will be measured using
Cr-EDTA clearance or iohexol clearance. The
same method should be used throughout the
study for a given patient.
• Calculated glomerular filtration rate (cGFR):
The GFR calculated according to the MDRD
(Modification of Diet in Renal Disease Study
Group) method [12, 13] will be used as a
secondary outcome measure in this study.
The calculated GFR is expressed in ml/min
per 1.73 m2.
• Rejection episodes and graft loss: All suspected
rejection episodes will be recorded in the
adverse event (AE) module in the eCRF,
whether a biopsy was performed, whether
follow-up biopsies were performed, whether
anti-rejection therapy was administered,
whether the acute rejection was confirmed
or with final clinical diagnosis specified, and
final clinical outcome.
Biopsy-Proven Acute Rejection
In all suspected rejection episodes, a trans-
bronchial biopsy will be done according to
local practice prior to or at the latest
within 24 h after the initiation of anti-
rejection therapy. Biopsies will be read and
interpreted by local pathologists. A biopsy-
proven acute rejection will be defined as a
biopsy graded A1–A4 or antibody-medi-
ated rejection according to International
Society of Heart and Lung Transplantation
(ISHLT) classification [14].
Graft Loss
Graft loss is considered a serious adverse
event (SAE) and should be reported in the
SAE module, and the reason for graft loss
should be recorded thoroughly.
• Primary graft dysfunction: Primary graft
dysfunction (PGD) is defined according
to ISHLT definition as pulmonary infil-
trates and hypoxemia occurring in the
first 72 h after transplantation [15].
Because chest x-ray has a low sensitivity
to detect interstitial changes in trans-
planted lungs, follow-up will include
high-resolution computed tomography
Table 4 continued
Period Period 1 Period 2
Visit 1 2 3 4 5 6 7 8 9 10
Week/month Pre-
LTx
LTx W1 W4 M3 M6 M9 M12 M24 M36
OGTT x x x x x
SORT analysis x x x x x x x x x
Weight-to-height ratio x x x x x x x x
Cytokines and inﬂammatory variables x x x x x x
LTx lung transplantation, W week, HLA human leucocyte antigen, ab antibody, DSA donor-speciﬁc antibodies, DLCO
diffusing capacity of the lung for carbon monoxide, VOL lung volumes, PCR polymerase chain reaction, cGFR calculated
glomerular ﬁltration rate, mGFR measured GFR, HR-CT high resolution computer tomography, Cya cyclosporine, Tac
tacrolimus, PAH pulmonary arterial hypertension, DNA deoxyribonucleic acid, RNA ribonucleic acid, OGTT oral glucose
tolerance test
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Table 5 Immunosuppressive regime in the ScanCLAD trial. Patients will be randomized in a 1:1 ratio into two groups, A
and B
Group A: cyclosporine A, MMF, and corticosteroids
Induction therapy: Thymoglobulin (1.5 mg/kg given immediately postoperatively). Antihistamine (Tavegyl) or
similar at a dose of 2 mg iv before induction therapy is initiated
Cyclosporine A: given orally pretransplant at a dose of 2–3 mg/kg
Continued postop day 1 (24 h postoperatively) at a dose of 3 mg/kg2, according to local practice and blood
concentration: 0–3 months, 250–300; 3–6 months, 200–250; 6–12 months, 150–200;[ 12 months 100–150 ng/
ml. Cyclosporine A will be administered twice daily
MMF target dose 2000 mg/day (1 g 9 2)
Controlled by a single area under the curve (AUC) measurement on day 90 with a target AUC between 40 and
60 mg h/L and corrected accordingly
Corticosteroids
Day 0 (day of lung transplantation); 500 ? 500 mg methylprednisolone iv before reperfusion, i.e., restoration of
blood ﬂow into the transplanted allograft
From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg/day 1–6 months; less than 0.1 mg/kg/day
[ 3–6 months
Group B: tacrolimus (Advagraf), MMF, and corticosteroids
Induction therapy: Thymoglobulin (1.5 mg/kg given immediately postoperatively). Antihistamine (Tavegyl) or
similar should be started at a dose of 2 mg iv before induction therapy is initiated
Tacrolimus (Advagraf)
Tacrolimus should be given orally pretransplant at a dose of 0.05–0.1 mg/kg
Continued postop day 1 (24 h postoperatively) at a dose of 0.1–0.2 mg/kg/24 h. To allow tacrolimus blood
concentrations to stabilize, Adport (or any tacrolimus galenic form) should be ordered BiD for the ﬁrst 3–7 days,
or prolonged if long ICU stay is required, and patient should be switched to the investigational drug Advagraf
OD at the ward or just prior to being discharged from ICU, and subsequently managed according to blood
concentration levels: 0–3 months, 10–14, 3–6 months, 8–12; 6–12 months, 8–10;[ 12 months, 6–8 ng/ml
MMF target dose 2000 mg/day (1 g 9 2)
Controlled by a single AUC measurement day 90 with a target AUC between 40 and 60 mg h/L and corrected
accordingly
Corticosteroids
Day 0; 500 ? 500 mg methylprednisolone iv before reperfusion, i.e., restoration of blood ﬂow into the transplanted
allograft
From day 1: initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg/day 1–6 months; less than 0.1 mg/kg/day
[ 3–6 months
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(HR-CT) on day 3 at definition of PGD
and subsequent follow-up at months 3
and 12 where bronchoscopy with trans-
bronchial biopsy (TBB) is available for
correlation study. A validated scoring
system, which has been used in a
previous prospective study of PGD, will
be applied [16, 17].
• Measurements of inflammatory variables:
Cytokines and other inflammatory vari-
able will be analyzed in plasma/serum
enzyme immunoassays or Luminex
multiplex assay. Serum and plasma sam-
ples will be taken before transplanta-
tion, at 1, 4, and 12 weeks, and at 6 and
12 months post-transplant and cryopre-
served at - 80 C for later analyses. All
analyses will be performed at a central
laboratory in Oslo, Norway. Standard
inflammatory cytokines/chemokines
and complement activation will be mea-
sured as previously described [18].
• Measurements of donor-specific antibodies:
The human leukocyte antigen (HLA)
antibody status and the presence of
donor-specific HLA antibodies (DSA)
before transplantation and produced
de novo at 4 weeks, 3 and 12 months,
and 2 and 3 years post-transplantation
will be analyzed using standard
methodology already in use in the
tissue typing lab at Sahlgrenska Univer-
sity Hospital. All tests will be performed
in one laboratory to avoid interlabora-
tory variation. Collected samples will
be stored at - 80 C for additional
analyses if new tests for other antigens
appear on the market.
• Functional assessments: A 6-minute walk
test (6MWT) is a functional test that
may be performed in the hallway or on
the treadmill in a standardized manner.
• Quality of life assessments: Two standard-
ized questionnaires, EQ5D3L and The St.
George’s Respiratory Questionnaire
(SGRQ), will be used. Measurements will
be done prior to LTx and 1, 2, and 3 years
after lung transplantation.
• NODAT/PTDM: New-onset diabetes
after transplantation (NODAT) or post-
transplantation diabetes mellitus
(PTDM) [19] will be assessed by oral
glucose tolerance test (OGTT) pre-Tx
and at 6, 12, 24, and 36 months after
transplantation.
RESULTS
Safety Assessment
Treatment with tacrolimus versus cyclosporine
has been shown to be safe and comparable
regarding early outcome such as rejection rates
and early mortality, as outlined in our literature
review [20]. However, there are few compre-
hensive studies and data on long-term outcome,
particularly on CLAD, is scarce.
Safety assessments will consist of monitoring
and recording all infections, any malignancies,
AEs, SAEs, and suspected unexpected serious
adverse reactions (SUSARs), the regular moni-
toring of hematology, blood chemistry, physi-
ological testing, and regular measurement of
vital signs. To ensure patient safety, every SAE,
regardless of suspected causality, occurring after
the patient is randomized and until 4 weeks
after the patient has stopped study participation
must be reported to the sponsor within 24 h or
at first possible weekday of learning of its
occurrence, whichever comes first.
Sample Size and Power Calculation
In order to detect a difference in CLAD between
the two treatment groups in the ScanCLAD
study, we calculated our sample size according
to the following assumptions: 2-year inclusion,
3-year follow-up, 80% power, and two-sided
significance level of 5%. On the basis of these
assumptions, the numbers needed were calcu-
lated as follows: CLAD incidence in CyA and
Tac arm of 30% (BOS alone approximately 30%
at 3 years [4] with cyclosporine) and 15% (50%
reduction was seen in the Treede study [3] with
Tac, although from 22% to 11%), respectively,
and 30% censuring (early dropouts) which
would require 121 patients in each arm, alto-
gether 242 patients in the study.
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Statistical Analyses
A statistical analysis plan (SAP) was written and
approved by the ethics committees (EC). All
analyses and tabulations will be performed
using the latest release of Stata software statis-
tical program (currently version 14.0). The
analysis will be done when all patients have
completed the trial at 36 months after LTx (or
discontinued prematurely). Unless otherwise
stated, all statistical tests will be two-sided and
use the 5% level of statistical significance.
Confidence intervals will be presented with
95% as the level of confidence. All summary
statistics will be presented for the treatment
groups. Frequency distributions will be pro-
vided for categorical variables and the two
treatment groups will be compared with the
chi-square or Fisher’s exact test. Descriptive
statistics of mean, standard deviation, mini-
mum, median and maximum will be presented
for continuous variables; comparison of the two
treatment groups will be performed with suit-
able chosen two-sample tests. Time to event
data including rates of affected patients will be
assessed by Kaplan–Meier statistics and com-
pared between the two groups with the log rank
test. Cumulative incidence will also be analyzed
by competing risk methods when competing
risks are present and will be compared between
the two groups with the Fine and Gray’s test or
similar test. Data from all centers that partici-
pate in this study will be combined.
Populations for Analysis
The enrolled patient (ENR) population will
include all patients who signed an informed
consent regardless of whether lung transplan-
tation was performed or not.
The intention-to-treat (ITT) population will
consist of all randomized patients. The ITT
population will be analyzed following the ITT
principle. However, this analysis is not the main
analysis of the study, since some patients will
inevitably be sent home without transplanta-
tion because of worsening of donor organ
function or other reasons, explained by the fact
that randomization occurs prior to transplan-
tation. The ITT population will therefore
include patients who never underwent trans-
plantation or received study drug.
The most important populations of study to
analyze are the following:
• The per protocol transplanted (PPtrans) pop-
ulation will consist of all patients in whom
transplantation was performed and who
were randomized and treated with at least
one dose of randomized treatment. The
PPtrans population is also the safety popula-
tion (SAF).
• The per protocol CLAD (PPCLAD) population
(or full-analysis set population, FAS) will
consist of all randomized patients who
received at least one dose of any immuno-
suppressive therapy, underwent transplanta-
tion, and had at least one post-baseline
assessment of the primary efficacy variable
(CLAD). Randomized patients without data
on the primary outcome variable will be
excluded from this population.
• The per protocol drug (PPdrug) population
will consist of all ITT patients who did not
show major deviations from the protocol
procedures that may have an impact on the
study outcome, remained on randomized
study drug, and who have completed the
treatment phase at 36 months according to
protocol.
Interim Analysis
There will be no planned interim analysis ini-
tiated by the steering committee; however, if
the data and safety monitoring board (DSMB)
wants one performed it can be done blinded.
Data Management
Randomization
The eCRF software creates the enrollment and
randomization numbers at enrollment and
randomization visits, respectively. Randomiza-
tion is performed using a web-based system and
patients are randomized in a 1:1 ratio to one of
the two treatment groups. Two sets of ran-
domization numbers will be prepared for strat-
ified randomization: (1) patients with a
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diagnosis of cystic fibrosis and (2) patients
without a diagnosis of cystic fibrosis.
Site Monitoring
During the study, a field monitor will visit the
site regularly to check the completeness of
patient records, the accuracy of entries in the
eCRFs, the adherence to the protocol and Good
Clinical Practice (GCP), and the progress of
enrollment. Monitoring standards are followed
and all checks of the consistency of the source
data with the CRFs are performed according to
the study-specific monitoring plan.
Data Collection
Gothia Forum, a non-profit organization asso-
ciated with Gothenburg University and
Sahlgrenska University Hospital, assists the
sponsor (GD) and all PIs in organizing the study
according to GCP rules. The study database is
placed on a central internet server. Designated
investigator staff will enter the data required by
the protocol into the database. Automatic vali-
dation programs check for data discrepancies in
the eCRFs and, by generating appropriate error
messages, allow modification or verification of
the entered data by the investigator staff before
being saved in the database.
Database Management and Quality Control
Gothia Forum will review the eCRFs entered by
investigational staff for completeness and
accuracy and instruct the site personnel to make
any required corrections or additions.
DISCUSSION
In brief, CLAD is currently defined as an irre-
versible drop in FEV1 to below 80% of baseline
FEV1 after LTx. In recent studies RAS seems to
account for approximately 30% of all CLAD and
BOS for the remaining 70% [6]. For qualifying as
RAS, lung function measurements also need to
show restrictive physiology, defined as an irre-
versible decline in TLC to below 90% of the
baseline TLC [6, 7, 21]. CLAD is one of the most
common causes of long-term deaths according
to the ISHLT registry [22].
A Cochrane review on tacrolimus use was
performed 6 years ago by the Copenhagen
group and showed that tacrolimus may be
superior to cyclosporine regarding BOS, treat-
ment withdrawal, and arterial hypertension,
but may be inferior regarding development of
diabetes. No difference in mortality and acute
rejection was observed between patients treated
with tacrolimus and cyclosporine [20].
CNIs, such as tacrolimus or cyclosporine, are
the cornerstones of immunosuppressive proto-
cols worldwide in LTx. There are well-known
side effects of these drugs, such as nephrotoxi-
city and an increased incidence of diabetes,
cardiovascular morbidity, and malignancy. All
centers are using CNIs after LTx; however, in
the last decade a switch has occurred worldwide
from cyclosporine to tacrolimus, according to
the ISHLT registry [4]. This change has occurred
even though there have been no real proof-of-
concept studies confirming that tacrolimus is
superior to cyclosporine with respect to long-
term survival after LTx. Controversy has existed
whether or not tacrolimus would result in fewer
rejections over time as indicated by registry data
but so far not shown in properly designed
studies in LTx patients. Therefore, cyclosporine
is still the CNI of choice in all Scandinavian
lung transplant programs. However, recently a
European–Australian prospective randomized
study showed that tacrolimus had a lower inci-
dence of BOS in LTx, after a 3-year follow-up [3].
The incidence of BOS decreased from approxi-
mately 21% to 11% at 3 years, despite the fact
that considerably more patients crossed over
from the cyclosporine group to the tacrolimus
group than vice versa. However, there was no
significant difference in survival between the
groups, which might have been related to the
high rate of crossover. We expect a lower
crossover rate in the Scandinavian study, com-
pared to Treede et al., which may impact sur-
vival if there is a true difference between the
studied drugs. In addition, our aim is to include
all adult patients eligible for de novo double
lung transplantation and without exclusion
criteria, in order to have minimal selection bias
and achieve a generalizable study in lung
transplantation. The ScanCLAD study has
caused synchronized programs in all
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Scandinavian lung transplant centers (five cen-
ters in four countries) both with regard to
treatment and examinations. We stand more
united with more than 150 lung transplanta-
tions per year.
In conclusion, we believe that clinical equi-
poise still exists regarding which CNI that
should be used after lung transplantation, and
that registry data and the few studies available
suffer from bias. In an attempt to improve the
low level of evidence, we have begun an inves-
tigator-initiated RCT regarding the preferred
CNI after LTx.
Fig. 2 Randomized patients at the end of April 2019 and stratiﬁed by center in the ScanCLAD study. GOT =
Gothenburg, Sweden; Lund = Lund, Sweden; CPH = Copenhagen, Denmark; HELS = Helsinki, Finland; and OSLO =
Oslo, Norway
1272 Adv Ther (2020) 37:1260–1275
Strengths and Limitations of the Study
This multicenter, randomized, open-label study
called the ScanCLAD study aims to include
most adult patients undergoing double lung
transplantation, and hopefully will add evi-
dence on which CNI will result in less CLAD
after lung transplantation. Not many studies
have been conducted on the choice of CNI in de
novo lung-transplanted patients, and this one is
also designed with a number of substudies. The
strengths of this study are that in a randomized
controlled fashion two drugs preventing rejec-
tion are compared regarding long-term CLAD at
3 years among five centers having the same
protocol after lung transplantation. Unlike
previous studies, ours will also comply with the
modern definition of CLAD. Furthermore, we
will have an adjudication committee regarding
the main outcome CLAD. Potential limitations
are the usual ones associated with a randomized
controlled study and also that it is not a double-
blind study, and therefore may introduce bias.
Current Study Status
The study was initiated in November 2016 in
Gothenburg, and subsequently all other sites
were started in sequence with the last one up
and running in July 2017. Since then 227
patients have been randomized (Fig. 2). Four
amendments to the study protocol have been
filed so far and approved by the EC in all
countries. The study is followed by a DSMB
group, consisting of Andrew Fisher, Jens Got-
tlieb, Eric Verschuuren, and Hans Wedel, that
oversees the study and meets every 6 months.
We are currently meeting our expected inclu-
sion rate and anticipate randomizing the last
patient sometime after the summer of 2019. The
planned last patient visit will be in 2022.
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